Posted on 06/08/2010 in Scientific Roche Diagnostics has provided technology and expertise to the Baylor College of Medicine Human Genome Sequencing Center in order to further research into the human genome and related diseases.
The US-based facility has worked with the science company's NimbleGen division to standardise its target enrichment human disease research studies on Roche sequence capture exome technology.
Over the next two years, Baylor will use the NimbleGen SeqCap EZ Exome to sequence more than 5,000 exomes, in order to better understand the relationship genetic mutations can have on diseases such as cancer, heart disease and diabetes.
The centre has been working with Roche for more than three years and praised the manufacturer for the "superb performance" of its technology.
Dr Andreas Gortz, vice-president of marketing at Roche NimbleGen, said: "We believe studies like these ... will provide insights on the missing heritability of many genetic diseases, hopefully leading to future breakthroughs in diagnostic and therapeutic tools."
Last month, Roche Diagnostics attended the American Association for Clinical Chemistry clinical lab expo to demonstrate a range of new technologies, including the cobas 8000 analyser series and the ACCU-CHEK Inform II unit. Other news stories from 06/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
